الفهرس 
EPIDEMIOLOGY AND RISK FACTORSOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Background: Lymphoma is the fourth most prevalent cancer among Egyptian adults, accounting for 76.6 percent non-Hodgkin lymphoma (NHL) and 23.4 percent Hodgkin lymphoma (HL). Most patients with classic Hodgkin lymphoma (cHL) achieve long-term survival free of HL, but late complications of treatment, such as second malignancies, cardiovascular disease, pulmonary disease, and other complications, have emerged as a competing cause of death and morbidity.
Aim of the Work: The aim of this work is to analyse retrospectively epidemiological and clinical outcomes of Hodgkin lymphoma patients treated in Ain Shams University hospitals (clinical oncology department) in Egypt in the period from January 2017 till December 2020.
Patients and Methods: This is a retrospective study that included 70 Hodgkin lymphoma patients who attended the lymphoma clinic at the Clinical Oncology Department, Ain Shams University. In the period between from January 2017 till December 2020. They either treated by chemotherapy only or chemotherapy and radiotherapy.
Result: Overall, of the 70 patients in the present study, 7 patients (10 %) died, and sixty-three patients (90 %) are alive till the end of our follow-up. The median OS is 34.54 months, while the median PFS is 15.67 months which is preliminary results. Many prognostic factors were selected for analysis to evaluate their impact on EFS. Some of these factors: age,gender, family history and special habits had no statistically significant impact on EFS. But other factors: ECOG status, staging, B-symptoms, interim PET CT and Radiotherapy had statistically significant impact on EFS.
Conclusion: Despite the increasing availability of guidelines for the treatment of HL, there is always a room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment (without any difference in long-term survival). Treatment should also be individualized when a particular approach might result in a higher risk of a serious late complication eg, the use of lung irradiation and the risk of late breast cancer in young females and of lung cancer in smokers.